Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B.

Ann Oncol. 2019 Jul 3. pii: mdz206. doi: 10.1093/annonc/mdz206. [Epub ahead of print]

PMID:
31268133
2.

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2019 Jul;121(3):283. doi: 10.1038/s41416-019-0512-8.

3.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
4.

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors.

Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, Wong P, Routy B.

Oncoimmunology. 2019 Feb 18;8(4):e1568812. doi: 10.1080/2162402X.2019.1568812. eCollection 2019.

PMID:
30906663
5.

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Chen J, Mehraj V, Szabo J, Routy B, Michel RP, Routy JP.

Curr Oncol. 2018 Dec;25(6):e592-e596. doi: 10.3747/co.25.4119. Epub 2018 Dec 1.

6.

The intimate relationship between gut microbiota and cancer immunotherapy.

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B.

Gut Microbes. 2019;10(3):424-428. doi: 10.1080/19490976.2018.1527167. Epub 2018 Oct 19.

7.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15. Erratum in: Br J Cancer. 2019 Jul;121(3):283.

8.

[In bacteria veritas: pronostic role of intestinal microbiote in cancer therapy].

Messaoudene M, Derosa L, Belkaid W, Routy B.

Med Sci (Paris). 2018 Aug-Sep;34(8-9):657-659. doi: 10.1051/medsci/20183408009. Epub 2018 Sep 19. French. No abstract available.

9.

Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients.

Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, Li J, Song X, Xie J, Qiu Z, Zhu T, Routy B, Routy JP, Li T, Zhu B.

Front Microbiol. 2018 Jul 2;9:1451. doi: 10.3389/fmicb.2018.01451. eCollection 2018.

10.

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.

Derosa L, Routy B, Kroemer G, Zitvogel L.

Oncoimmunology. 2018 Apr 18;7(6):e1434468. doi: 10.1080/2162402X.2018.1434468. eCollection 2018.

11.

The gut microbiota influences anticancer immunosurveillance and general health.

Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G.

Nat Rev Clin Oncol. 2018 Jun;15(6):382-396. doi: 10.1038/s41571-018-0006-2. Review.

PMID:
29636538
12.

The impact of the intestinal microbiota in therapeutic responses against cancer.

Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L.

C R Biol. 2018 May - Jun;341(5):284-289. doi: 10.1016/j.crvi.2018.03.004. Epub 2018 Apr 7. Review.

13.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

14.

Immuno-oncology-101: overview of major concepts and translational perspectives.

Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L.

Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Review.

PMID:
29428479
15.

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.

Williams BA, Law AD, Routy B, denHollander N, Gupta V, Wang XH, Chaboureau A, Viswanathan S, Keating A.

Oncotarget. 2017 Jul 12;8(51):89256-89268. doi: 10.18632/oncotarget.19204. eCollection 2017 Oct 24.

16.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
17.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

18.

Anticancer effects of the microbiome and its products.

Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G.

Nat Rev Microbiol. 2017 Aug;15(8):465-478. doi: 10.1038/nrmicro.2017.44. Epub 2017 May 22. Review.

PMID:
28529325
19.

The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.

Routy B, Letendre C, Enot D, Chénard-Poirier M, Mehraj V, Séguin NC, Guenda K, Gagnon K, Woerther PL, Ghez D, Lachance S.

Oncoimmunology. 2016 Dec 27;6(1):e1258506. doi: 10.1080/2162402X.2016.1258506. eCollection 2017.

20.

The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy.

Routy JP, Routy B, Graziani GM, Mehraj V.

Int J Tryptophan Res. 2016 Oct 12;9:67-77. eCollection 2016. Review.

21.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

22.

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L.

Immunity. 2016 Jun 21;44(6):1255-69. doi: 10.1016/j.immuni.2016.06.001. Review.

23.

Prime time for immune-checkpoint targeted therapy at ASCO 2015.

Marabelle A, Routy B, Michels J, Kroemer G, Zitvogel L.

Oncoimmunology. 2015 Aug 12;5(3):e1068494. eCollection 2016 Mar. Review.

24.

Microbiome and Anticancer Immunosurveillance.

Zitvogel L, Ayyoub M, Routy B, Kroemer G.

Cell. 2016 Apr 7;165(2):276-87. doi: 10.1016/j.cell.2016.03.001. Review.

25.

Immunological off-target effects of imatinib.

Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G.

Nat Rev Clin Oncol. 2016 Jul;13(7):431-46. doi: 10.1038/nrclinonc.2016.41. Epub 2016 Mar 31. Review.

PMID:
27030078
26.

Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review.

Cao W, Vyboh K, Routy B, Chababi-Atallah M, Lemire B, Routy JP.

Curr Oncol. 2015 Oct;22(5):e395-9. doi: 10.3747/co.22.2635.

27.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

29.

Pulmonary Langerhans Cell Histiocytosis with Lytic Bone Involvement in an Adult Smoker: Regression following Smoking Cessation.

Routy B, Hoang J, Gruber J.

Case Rep Hematol. 2015;2015:201536. doi: 10.1155/2015/201536. Epub 2015 Feb 18.

30.

Vascular endothelial cell function in catastrophic antiphospholipid syndrome: a case report and review of the literature.

Routy B, Huynh T, Fraser R, Séguin C.

Case Rep Hematol. 2013;2013:710365. doi: 10.1155/2013/710365. Epub 2013 May 15.

31.

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.

Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.

Am J Ther. 2013 Mar-Apr;20(2):219-22. doi: 10.1097/MJT.0b013e318258905e.

PMID:
23466621

Supplemental Content

Support Center